Table of Contents
Kali Therapeutics said March 23, 2026 that it entered a worldwide exclusive license agreement with Sanofi for KT501, a tri-specific T-cell engager being developed for a broad range of B cell-mediated autoimmune diseases.
Under the agreement, Sanofi will obtain exclusive worldwide rights to the asset. Kali will receive $180 million in upfront and near-term payments and remains eligible for up to $1.05 billion in development and commercial milestone payments, along with tiered royalties on product sales ranging from high-single to double digits.
KT501 is described by Kali as a novel IgG-like tri-specific T-cell engager designed to bind CD3, CD19, and BCMA with high affinity, targeting a broad range of B cell populations. The company said the candidate uses its CD3 masking platform, with a molecular design intended to maximize potency while minimizing cytokine release. In non-human primate studies, Kali reported potent B cell depletion in peripheral systems and tissues, alongside significantly reduced cytokine production.
As of March 23, KT501 is being evaluated in a first-in-human study in participants with rheumatoid arthritis. The study is assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
Source: Kali Therapeutics
Comments